Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Neos Therapeutics, Inc. (NEOS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/29/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 03/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/22/2021 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur...|
Docs:
|
"Fifth Amended and Restated Certificate of Incorporation of Neos Therapeutics, Inc",
"Second Amended and Restated Bylaws of Neos Therapeutics, Inc",
"Consent, Waiver and Sixth Amendment to Facility Agreement, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, LLC, Deerfield Private Design Fund III L.P., Deerfield Partners, L.P. and Deerfield Mgmt, L.P.",
"Consent, Waiver and Amendment No. 1 to Loan and Security Agreement, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, and Encina Business Credit, LLC",
"Aytu BioScience Announces Close of Merger with Neos Therapeutics" |
|
| 03/22/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/19/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/19/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/19/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/19/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/19/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/19/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/19/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/19/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/12/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 03/12/2021 |
GN
| Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience |
| 03/10/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/16/2021 |
SC 13G/A
| SPHERA FUNDS MANAGEMENT LTD. reports a 0% stake in Neos Therapeutics, Inc. |
| 02/12/2021 |
SC 13G/A
| Stonepine Capital Management, LLC reports a 10% stake in Neos Therapeutics, Inc. |
| 02/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 02/10/2021 |
GN
| Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 |
| 02/09/2021 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 02/08/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/08/2021 |
8-K
| Quarterly results |
| 01/11/2021 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/11/2021 |
8-K
| Quarterly results |
| 12/30/2020 |
425
| Form 425 - Prospectuses and communications, business combinations: |
|
|
|